Pays: Canada
Langue: anglais
Source: Health Canada
LEUPROLIDE ACETATE
ABBVIE CORPORATION
L02AE02
LEUPRORELIN
11.25MG
POWDER FOR SUSPENSION, SUSTAINED-RELEASE
LEUPROLIDE ACETATE 11.25MG
INTRAMUSCULAR
100
Prescription
GONADOTROPINS
Active ingredient group (AIG) number: 0116959003; AHFS:
CANCELLED PRE MARKET
2016-06-22
_LUPRON and LUPRON DEPOT _ _Page 1 of 54 _ PRODUCT MONOGRAPH PR LUPRON ® leuprolide acetate injection 5 mg/mL PR LUPRON DEPOT ® leuprolide acetate for depot suspension pre-filled dual-chamber syringe containing sterile lyophilized microspheres 7.5 mg/syringe (1-Month slow release), 22.5 mg/syringe (3-Month slow release), 30.0 mg/syringe (4-Month slow release) Gonadotropin-releasing hormone analog AbbVie Corporation Date of Revision: 8401 Trans-Canada Highway January 3, 2018 St-Laurent, Qc H4S 1Z1 Submission Control No: 210907 _LUPRON and LUPRON DEPOT _ _Page 2 of 54 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................4 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................10 DRUG INTERACTIONS ..................................................................................................17 DOSAGE AND ADMINISTRATION ..............................................................................18 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................24 SPECIAL HANDLING INSTRUCTIONS .......................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................24 PART II: SCIENTIFIC INFORMATION ........ Lire le document complet